Active Filter(s):
Details:
PLX038 (PEG~SN-38) is a long-acting PEGylated prodrug of SN-38, the active metabolite of the approved anti-cancer agents irinotecan and Trodelvy® (sacituzumab govitecan). SN-38 is a potent inhibitor of topoisomerase 1 (topo1) that causes inhibition of DNA synthesis leading to cell death in susceptible tumors.
Lead Product(s): 7-Ethyl-10-Hydroxycamptothecin
Therapeutic Area: Oncology Product Name: PLX038
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: National Cancer Institute
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 07, 2022
Details:
PLX038 (PEG~SN-38) is a long-acting PEGylated prodrug of SN-38, the active metabolite of the approved anti-cancer agents irinotecan and Trodelvy® (sacituzumab govitecan). SN-38 is a potent inhibitor of topoisomerase 1 (topo1) that causes inhibition of DNA synthesis leading to cell death in susceptible tumors.
Lead Product(s): 7-Ethyl-10-Hydroxycamptothecin,Rucaparib Camsylate
Therapeutic Area: Oncology Product Name: PLX038
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 13, 2020